Disc Medicine (NASDAQ:IRON) Stock Rating Upgraded by Wall Street Zen

Disc Medicine (NASDAQ:IRON) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Morgan Stanley lifted their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Finally, Wedbush reissued an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $104.44.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $77.00 on Friday. The stock has a market capitalization of $2.94 billion, a P/E ratio of -11.70 and a beta of 1.00. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $72.74 and a two-hundred day moving average price of $69.62. Disc Medicine has a 12-month low of $40.00 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. Equities analysts expect that Disc Medicine will post -6.75 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $69.19, for a total transaction of $1,287,764.28. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at $3,758,677.56. The trade was a 25.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rahul Khara sold 7,500 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00. Following the transaction, the insider directly owned 52,173 shares in the company, valued at $3,663,588.06. This trade represents a 12.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 105,712 shares of company stock valued at $7,597,536 in the last three months. Company insiders own 3.76% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Handelsbanken Fonder AB acquired a new position in shares of Disc Medicine during the second quarter valued at about $929,000. Seven Fleet Capital Management LP acquired a new stake in Disc Medicine during the first quarter worth about $207,000. Bank of America Corp DE raised its holdings in Disc Medicine by 22.6% in the 1st quarter. Bank of America Corp DE now owns 166,775 shares of the company’s stock valued at $10,664,000 after acquiring an additional 30,789 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Disc Medicine by 47.8% in the 1st quarter. California State Teachers Retirement System now owns 34,382 shares of the company’s stock worth $2,198,000 after acquiring an additional 11,126 shares during the period. Finally, SummitTX Capital L.P. bought a new stake in shares of Disc Medicine in the 1st quarter worth approximately $884,000. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.